VistaGen Therapeutics(US:VTGN) ZACKS·2025-08-08 00:21Core Insights - VistaGen Therapeutics, Inc. reported a quarterly loss of $0.47 per share, matching the Zacks Consensus Estimate, compared to a loss of $0.35 per share a year ago [1] - The company generated revenues of $0.24 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 62.46%, but showing an increase from $0.08 million year-over-year [2] - The stock has underperformed the market, gaining about 0.7% year-to-date compared to the S&P 500's gain of 7.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.51 on revenues of $0.49 million, and for the current fiscal year, it is -$1.66 on revenues of $1.77 million [7] - The estimate revisions trend for VistaGen Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which VistaGen belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]